With more than 25 years at Kaiser Permanente Washington Health Research Institute (KPWHRI), Laura Ichikawa, MS, is known for her analytical skills, attention to detail regarding study design and data management, and expertise in data visualization. Her experience includes observational studies, randomized controlled trials, case-control studies, and multisite analyses.
Laura is primarily focused on cancer research and women’s health. She’s involved in 2 large, multisite National Cancer Institute-funded projects: the Statistical Coordinating Center for the Breast Cancer Surveillance Consortium (BCSC) and a colorectal research site for Population-based Research to Optimize the Screening Process (PROSPR). Much of her work with the BCSC has been evaluating mammography performance for both screening and surveillance while also examining use of screening MRI (magnetic resonance imaging) and ultrasound. Laura also participated in collaborative research through the Cancer Research Network, including a widely publicized 2004 study that linked not having screening mammograms to late-stage breast cancer. She is excited to continue her work in cancer research, including in screening, treatment, surveillance, and survival.
Laura’s earlier research with retired KPWHRI Senior Investigator Delia Scholes, PhD, included studies examining bone loss associated with the injectable hormonal contraceptive Depo-Provera in 2002 and 2005 and oral contraceptives in 2011.
Laura is a member of the American Statistical Association and its Puget Sound chapter.
Longitudinal data analysis
Biostatistics; breast cancer
Biostatistics; hormonal contraception and bone density
Taplin SH, Ichikawa L, Kerlikowske K, Ernster V, Rosenberg R, Yankaskas B, Carney P, Geller B, Urban N, Dignan M, Barlow WE, Ballard-Barbash R. Concordance of BI-RADS (Breast Imaging Reporting and Data System) assessments and management recommendations in screening mammography. Radiology. 2002;222:529-535. PubMed
Ott SM, Scholes D, LaCroix AZ, Ichikawa LE, Yoshida CK, Barlow WE. Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab. 2001;86(1):179-85. PubMed
LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;133(7):516-26. PubMed
Civic D, Scholes D, Ichikawa L, LaCroix AZ, Yoshida CK, Ott SM, Barlow WE. Depressive symptoms in users and non-users of depot medroxyprogesterone acetate. Contraception. 2000;61(6):385-90. PubMed
Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 1999;93(2):233-8. PubMed
Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12):1165-72. PubMed
Treiman GS, Schneider PA, Lawrence PF, Pevec WC, Bush RL, Ichikawa L. Does stent placement improve the results of ineffective or complicated iliac artery angioplasty? J Vasc Surg. 1998;28(1):104-12; discussion 113-4. PubMed
Scholes D, Stergachis A, Ichikawa LE, Heidrich FE, Holmes KK, Stamm WE. Vaginal douching as a risk factor for cervical Chlamydia trachomatis infection. Obstet Gynecol. 1998;91(6):993-7. PubMed
Keech PM, Ichikawa L, Barlow W. A prospective study of contact lens complications in a managed care setting. Optom Vis Sci. 1996;73(10):653-8. PubMed
Treiman GS, Treiman RL, Ichikawa L, Van-Allen R. Should percutaneous transluminal angioplasty be recommended for treatment of infrageniculate popliteal artery or tibioperoneal truck stenosis? J Vasc Surg. 1995;22(4):457-63. PubMed
New study results in more precise language in the federally mandated warning about this possibility.
A Kaiser Permanente-led BCSC study is among the largest ever to evaluate adding MRI surveillance for breast cancer survivors.
New KPWHRI study shows that women with simple cysts are not at increased risk of ovarian cancer.
Dr. Katherine Newton co-wrote JAMA Internal Medicine paper comparing vaginal estrogen, moisturizer, and placebo gel.